Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
Matthew Ryan CarrollPreetha RamalingamGloria SalvoJunya FujimotoLuisa Maren Solis SotoNatacha PhoolcharoenRobert Tyler HillmanRobert CardnellLauren ByersMichael FrumovitzPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)
Pure high-grade neuroendocrine cervical carcinomas were microsatellite stable and overwhelmingly negative for PD-L1 expression. As the majority of tumors tested expressed PARP-1, inclusion of PARP inhibitors in future clinical trials may be considered.